233 related articles for article (PubMed ID: 27199249)
1. Patent watch: Diagnostic patents at risk after Federal Circuit decisions.
Noonan K
Nat Rev Drug Discov; 2016 Jun; 15(6):377. PubMed ID: 27199249
[No Abstract] [Full Text] [Related]
2. Patent watch: Progress in three key patent disputes in 2009.
Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395
[No Abstract] [Full Text] [Related]
3. Patent prosecution of biotechnology and pharmaceutical patents in a changing legal landscape.
Lu DL; Kowalski TJ; Jarecki-Black J
Future Med Chem; 2010 Jan; 2(1):7-9. PubMed ID: 21426040
[No Abstract] [Full Text] [Related]
4. Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1).
Tsao R; Hurley EA
Nat Biotechnol; 1997 Jan; 15(1):86-7. PubMed ID: 9035112
[No Abstract] [Full Text] [Related]
5. Patent crunch pending.
Wadman M
Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
[No Abstract] [Full Text] [Related]
6. Patent fight sparks biological warfare in the drug industry.
Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
[No Abstract] [Full Text] [Related]
7. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
Furrow ME
Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
[No Abstract] [Full Text] [Related]
8. Diagnostic method patents and harms to follow-on innovation.
Harv Law Rev; 2013 Mar; 126(5):1370-91. PubMed ID: 25330558
[No Abstract] [Full Text] [Related]
9. Cabilly patent finale.
Waltz E
Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
[No Abstract] [Full Text] [Related]
10. The ITC as an attractive patent litigation forum for the biotechnology and pharmaceutical industry.
Burton CA; Margonis LE
Pharm Pat Anal; 2013 Mar; 2(2):177-80. PubMed ID: 24237023
[No Abstract] [Full Text] [Related]
11. Proposed changes to patent code loom over biotech industry.
Coombs A
Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
[No Abstract] [Full Text] [Related]
12. Biotechnology patent disputes. Market machinations.
Gershon D
Nature; 1990 Apr; 344(6269):800. PubMed ID: 2330035
[No Abstract] [Full Text] [Related]
13. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech.
Garber K
Science; 2006 May; 312(5775):827. PubMed ID: 16690824
[No Abstract] [Full Text] [Related]
14. Roche faces charges over Taq patent claim.
Abbott A
Nature; 1996 Aug; 382(6593):660. PubMed ID: 8751427
[No Abstract] [Full Text] [Related]
15. US courts narrow patent exemptions.
Fox JL
Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
[No Abstract] [Full Text] [Related]
16. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
Teitelbaum R; Cohen M
Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
[No Abstract] [Full Text] [Related]
17. "Ganske" threatens biotechnology patents worldwide.
Glaser V
Nat Biotechnol; 1997 Feb; 15(2):121. PubMed ID: 9035128
[No Abstract] [Full Text] [Related]
18. Innovators working hard to avoid patent exclusions in the US.
Tombling A
Drug Discov Today; 2013 Dec; 18(23-24):1131-2. PubMed ID: 24120891
[No Abstract] [Full Text] [Related]
19. Patent drop reveals pressures on industry.
Lawrence S
Nat Biotechnol; 2004 Aug; 22(8):930-1. PubMed ID: 15286630
[No Abstract] [Full Text] [Related]
20. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
